

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
19 September 2024 (19.09.2024)



(10) International Publication Number  
**WO 2024/189488 A1**

(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/445 (2006.01)  
C07D 471/04 (2006.01) A61K 31/506 (2006.01)  
A61P 35/00 (2006.01) A61K 31/513 (2006.01)

(21) International Application Number:

PCT/IB2024/052251

(22) International Filing Date:

08 March 2024 (08.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/489,528 10 March 2023 (10.03.2023) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85, Södertälje (SE).

(72) Inventors: **ASTLES, Peter**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **SCOTT, James**; c/o AstraZeneca UK Limited, 1 Francis Crick


Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **WALTON, Laura**; ASTRAZENECA INTELLECTUAL PROPERTY, Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS



(I)

(57) Abstract: A compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein: X<sup>1</sup> is CH or N; p is 0, 1 or 2; where: each R<sup>1</sup> is a substituent on any C atom and is independently selected from F, Cl, C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy, wherein said C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy may be independently optionally substituted by one or more F; R<sup>N</sup> is selected from H and Me; n is 0, 1 or 2; m is 0 or 1; Q<sup>1</sup> is CH or N; when n & m are both other than 0, Q<sup>2</sup> is CH or N; when n & m are both 0, Q<sup>2</sup> is CH; when n is 0 or 1, Q<sup>3</sup> is CH; when n is 2 and Q<sup>2</sup> is N, Q<sup>3</sup> is CH; when n is 2 and Q<sup>2</sup> is CH, Q<sup>3</sup> is CH or O; R<sup>2a</sup> and R<sup>2b</sup> are substituents on the same or different C atoms other than at Q<sup>1</sup> or Q<sup>2</sup>, each independently selected from H, F and C<sub>1-3</sub>alkyl, or R<sup>2a</sup> & R<sup>2b</sup> together form a -(CH<sub>2</sub>)<sub>r</sub>- group where r is 1, 2 or 3; Q<sup>4</sup> is a single bond or -NR<sup>4</sup>C(=O); R<sup>4</sup> is H or Me; 0, 1 or 2 of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, Y<sup>4</sup> & Y<sup>5</sup> is/are N, and are otherwise C; each R<sup>3</sup> is a substituent on any C atom at Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, Y<sup>4</sup> & Y<sup>5</sup>, and is independently selected from F, Cl, CN, C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy, wherein said C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy may be independently optionally substituted by one or more F; q is 0, 1 or 2; wherein Linker is attached at any available C atom at Y<sup>4</sup> & Y<sup>5</sup>; Linker is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment 'a' and 'b' and a length of from 5 to 26 atoms between 'a' and 'b'; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*